The Specialized Cancer Center at Mount Sinai School of Medicine continues its work in immunologic diagnosis of breast cancer, analytical chemical diagnosis of fungal and bacterial infection and pathologic diagnosis of cells of interest by electronmicroscopy characteristics. Pharmacology of human cell lines in vitro in their native state and in the induced resistance state are conducted. Major emphasis has been placed on folic acid antagonists resistance and 2.4. diamminopyridine collateral sensitivity. Drug testing on human mesothelioma explanted into athymic mice continues. Investigation of electromagnetic radiation on chemotherapeutic effect on animal tumors is in progress. Clinical pharmacology of citrovorum and its modulation of 5-fluorouracil chemotherapeutic activity has begun. Controlled comparisons of cisplatin and doxorubicin versus cisplatin, doxorubicin and cyclophosphamide in ovarian cancer is in progress. A new trial comparing methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) versus MEPH (mitocycin, etoposide, cisplatin and hexamethylmelamine) followed by MACC offers a new lead in lung cancer, since MEPH has been recognized to demonstrate activity even after MACC failure. Studies of chemotherapy in an adjuvant setting of breast cancer and of colon cancer continues. Exploratory techniques of treating brain tumors have begun. Mathematical modeling of anticipated outcome has been progressively used to design regimens worthy of clinical tests. Such regimens, pioneered in the Cancer Center, have been extrapolated to Cooperative Study Groups for further implementation. The organizaion and interrelationships within the Cancer Center have significantly improved this past year, and a more cohesive effort across the entire Medical School is now evident. This application is submitted for continued support of the administration of the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023102-08
Application #
3101716
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1979-07-01
Project End
1989-11-30
Budget Start
1986-12-01
Budget End
1989-11-30
Support Year
8
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Paciucci, P A; Ryder, J S; Mandell, J P et al. (2000) Interleukin-2 plus chemotherapy for patients with metastatic melanoma. Melanoma Res 10:291-5
Puolakkainen, P; Twardzik, D; Ranchalis, J et al. (1995) Increase of plasma transforming growth factor beta (TGF beta) during immunotherapy with IL-2. Cancer Invest 13:583-9
Silverman, L R; Deligdisch, L; Mandeli, J et al. (1994) Chemotherapy for angiosarcoma of the breast: case report of 30-year survival and analysis of the literature. Cancer Invest 12:145-55
Bhardwaj, S; Holland, J F; Norton, L (1993) An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest 11:6-9
Paciucci, P A; Bekesi, J G; Ryder, J S et al. (1991) Immunotherapy with IL2 by constant infusion and weekly doxorubicin. Am J Clin Oncol 14:341-8
Head, J F; Chahinian, A P; Greengard, O (1991) Enzymic composition and growth rate of human pleural mesothelioma transplants in nude mice. Cancer Biochem Biophys 12:127-36
Crown, J; Lipzstein, R; Cohen, S et al. (1991) Chemotherapy of metastatic Merkel cell cancer. Cancer Invest 9:129-32
Oleksowicz, L; Paciucci, P A; Zuckerman, D et al. (1991) Alterations of platelet function induced by interleukin-2. J Immunother (1991) 10:363-70
Bruckner, H W; Cohen, C; Mandeli, J et al. (1991) Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience. Cancer Treat Rev 18 Suppl A:57-65
Yagi, M J; Bekesi, J G (1990) Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia. Cancer Chemother Pharmacol 26:215-20

Showing the most recent 10 out of 55 publications